Insights Into the Proteomic Profiling of Extracellular Vesicles for the Identification of Early Biomarkers of Neurodegeneration
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles (EVs) are involved in the development and progression of neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Moreover, EVs have the capacity to modify the physiology of neuronal circuits by transferring proteins, RNA, lipids, and metabolites. The proteomic characterization of EVs (exosomes and microvesicles) from preclinical models and patient samples has the potential to reveal new proteins and molecular networks that affect the normal physiology prior to the appearance of traditional biomarkers of neurodegeneration. Noteworthy, many of the genetic risks associated to the development of Alzheimer's and Parkinson's disease affect the crosstalk between mitochondria, endosomes, and lysosomes. Recent research has focused on determining the role of endolysosomal trafficking in the onset of neurodegenerative diseases. Proteomic studies indicate an alteration of biogenesis and molecular content of EVs as a result of endolysosomal and autophagic dysfunction. In this review, we discuss the status of EV proteomic characterization and their usefulness in discovering new biomarkers for the differential diagnosis of neurodegenerative diseases. Despite the challenges related to the failure to follow a standard isolation protocol and their implementation for a clinical setting, the analysis of EV proteomes has revealed the presence of key proteins with post-translational modifications that can be measured in peripheral fluids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ngolab, J., Trinh, I., Rockenstein, E., Mante, M., Florio, J., Trejo, M., Masliah, D., Adame, A., Masliah, E., & Rissman, R. A. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0445-5 · Cited by 200
RetractedPoewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Reassessment of exosome composition
Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., Liebler, D. C., Ping, J., Liu, Q., Evans, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.029 · Cited by 2,975
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 1×
“The inhibition of exosome synthesis in microglia significantly reduces Tau propagation in vitro and in vivo (115).”
BackgroundThe global burden of neurological disorders: translating evidence into policy
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30411-9 · Cited by 1,303
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112 · cited 2×
“Similar evidence has been described for PD in which the dysfunction of key elements of lysosomal and endosomal pathways has been associated with the development of the disease (7).”
BackgroundSaman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985 · cited 1×
“In AD, the increased production of EVs is associated with the progression of Tau pathology (111, 114).”
BackgroundFiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Exosomes are released by cultured cortical neurones
Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.003 · Cited by 896 · cited 2×
“The EVs purified from N2a, SHSY-5Y, and cortical neurons, highly enriched in PrPC, show a higher binding affinity for dimeric, pentameric, and oligomeric Aβ species (103, 104).”
BackgroundThe genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
Mahul-Mellier, A.-L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913904117 · Cited by 710
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation
Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., Fazel, A., Bergeron, J. J., Trudeau, L.-E., Burelle, Y., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.039 · Cited by 582 · cited 2×
“The analysis of circulant mitochondrial-derived vesicles can be promising for the identification of early biomarkers of PD, considering that it is a cellular mechanism of antigen presentation in inflammatory conditions (73).”
BackgroundAlzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527 · cited 1×
“In human brain sections from AD patients, the exosome marker flotillin-1 colocalizes with oligomers of Aβ (57).”
BackgroundRetrovirus-like Gag Protein Arc1 Binds RNA and Traffics across Synaptic Boutons
Ashley, J., Cordy, B., Lucia, D., Fradkin, L. G., Budnik, V., & Thomson, T. (2018) · Cell · doi:10.1016/j.cell.2017.12.022 · Cited by 488
Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease
Shannon, K. M., Keshavarzian, A., Mutlu, E., Dodiya, H. B., Daian, D., Jaglin, J. A., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.23838 · Cited by 469 · cited 1×
“α-syn pathology initiates in the periphery even earlier than in the central nervous system (68, 69).”
BackgroundTrans-Synaptic Transmission of Vesicular Wnt Signals through Evi/Wntless
Korkut, C., Ataman, B., Ramachandran, P., Ashley, J., Barria, R., Gherbesi, N., & Budnik, V. (2009) · Cell · doi:10.1016/j.cell.2009.07.051 · Cited by 443
Extracellular Vesicles and Neurodegenerative Diseases
Hill, A. F. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0147-18.2019 · Cited by 437
Men, Y., Yelick, J., Jin, S., Tian, Y., Chiang, M. S. R., Higashimori, H., Brown, E., Jarvis, R., & Yang, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-11534-w · Cited by 357 · cited 2×
“Neuron-derived EVs containing GFP are incorporated preferentially by astrocytes and also in a minor proportion by certain neurons, both in vivo and in vitro experiments (25, 26).”
BackgroundDickens, A. M., Tovar-y-Romo, L. B., Yoo, S.-W., Trout, A. L., Bae, M., Kanmogne, M., Megra, B., Williams, D. W., Witwer, K. W., Gacias, M., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aai7696 · Cited by 285 · cited 1×
“In addition, the activation of astrocytes by IL-1β is associated with the production of vesicles that are released into peripheral circulation and that promote migration of leukocytes into the brain (30).”
BackgroundMinakaki, G., Menges, S., Kittel, A., Emmanouilidou, E., Schaeffner, I., Barkovits, K., Bergmann, A., Rockenstein, E., Adame, A., Marxreiter, F., et al. (2018) · Autophagy · doi:10.1080/15548627.2017.1395992 · Cited by 272
Söllvander, S., Nikitidou, E., Brolin, R., Söderberg, L., Sehlin, D., Lannfelt, L., & Erlandsson, A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0098-z · Cited by 267
Regulation of Postsynaptic Retrograde Signaling by Presynaptic Exosome Release
Korkut, C., Li, Y., Koles, K., Brewer, C., Ashley, J., Yoshihara, M., & Budnik, V. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.013 · Cited by 250 · cited 1×
“The release of EVs from the presynaptic terminal is activity dependent and promotes the delivery of molecules to the post-synapsis such as Synaptotagmin-4, which, by retrograde signaling, promotes the maturation of the presynaptic terminal at the neuromuscular junction of Drosophila (20, 21).”
Backgroundde Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214
Pastuzyn, E. D., Day, C. E., Kearns, R. B., Kyrke-Smith, M., Taibi, A. V., McCormick, J., Yoder, N., Belnap, D. M., Erlendsson, S., Morado, D. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.024 · Cited by 213 · cited 1×
“Likewise, synaptic plasticity is influenced by EV-mediated transfer of Arc1 mRNA to the post-synaptic region (22, 23).”
BackgroundShi, M., Kovac, A., Korff, A., Cook, T. J., Ginghina, C., Bullock, K. M., Yang, L., Stewart, T., Zheng, D., Aro, P., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.003 · Cited by 206
Chaudhuri, A. D., Dastgheyb, R. M., Yoo, S.-W., Trout, A., Talbot Jr, C. C., Hao, H., Witwer, K. W., & Haughey, N. J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0369-4 · Cited by 184
BIN1 favors the spreading of Tau via extracellular vesicles
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45676-0 · Cited by 171 · cited 1×
“In animal models and CSF of AD, BIN1 is related to Tau secretion via EVs and could contribute to Tau pathology by altering Tau clearance and promoting the release of Tau enriched EVs by microglia (119).”
BackgroundProteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease
Wang, S., Kojima, K., Mobley, J. A., & West, A. B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.021 · Cited by 145 · cited 2×
“The measurement of these proteins have a prediction success in a range of 76–86% for disease diagnosis in two independent cohorts (96).”
BackgroundResultPrioritizing Parkinson’s disease genes using population-scale transcriptomic data
Li, Y. I., Wong, G., Humphrey, J., & Raj, T. (2019) · Nature Communications · doi:10.1038/s41467-019-08912-9 · Cited by 143
Eitan, E., Hutchison, E. R., Marosi, K., Comotto, J., Mustapic, M., Nigam, S. M., Suire, C., Maharana, C., Jicha, G. A., Liu, D., et al. (2016) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2016.19 · Cited by 129
Apolipoprotein E4 genotype compromises brain exosome production
Peng, K. Y., Pérez-González, R., Alldred, M. J., Goulbourne, C. N., Morales-Corraliza, J., Saito, M., Saito, M., Ginsberg, S. D., Mathews, P. M., & Levy, E. (2019) · Brain · doi:10.1093/brain/awy289 · Cited by 109 · cited 15×
“Moreover, EV levels of Aβ42 are an indicator of AD progression in preclinical cases (111).”
BackgroundInfluentialBaker, S., Polanco, J. C., & Götz, J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160371 · Cited by 98 · cited 1×
“Likewise, EVs from mice containing Tau with the familial dementia mutation P301L accelerate Tau phosphorylation and soluble aggregate formation in vivo (132).”
BackgroundDeng, J., Koutras, C., Donnelier, J., Alshehri, M., Fotouhi, M., Girard, M., Casha, S., McPherson, P. S., Robbins, S. M., & Braun, J. E. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-01115-6 · Cited by 70
Nikitidou, E., Khoonsari, P. E., Shevchenko, G., Ingelsson, M., Kultima, K., & Erlandsson, A. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170278 · Cited by 68
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37
Cited by
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., Falzone, G. G., Giachino, C., Marchetti, B., & Iraci, N. (2021) · Aging and disease · doi:10.14336/ad.2021.0527 · Cited by 55
Walecha, V., & Luthra, P. M. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04559-9 · Cited by 12
Metadata
- Authors
- Quiroz-Baez, R., Hernández-Ortega, K., & Martínez-Martínez, E.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2020-12-11
- Volume
- 11
- Pages
- 580030-580030
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W3110956641
- Cited by
- 49
- References
- 38
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.